Annexon Inc
ANNX2.475USD
+0.025+1.02%
交易中 （美东）报价延迟15分钟
271.54M总市值
亏损市盈率 TTM
关于 Annexon Inc 公司
Annexon, Inc. 是一家临床阶段的生物制药公司。该公司致力于推进针对患有经典补体介导的身体、大脑和眼睛神经炎症疾病患者的后期临床治疗平台。该公司利用其平台识别和描述补体途径在三个治疗领域的作用：自身免疫、神经退行性疾病和眼科。其主要候选药物 ANX005 是一种研究性单克隆抗体 (mAb)，在关键的 III 期临床试验中配制为静脉注射，用于治疗格林-巴利综合征 (GBS) 患者。该公司正在评估 ANX007，一种配制为玻璃体内注射的抗原结合片段 (Fab)，用于治疗地图状萎缩 (GA) 患者。该公司正在开发 ANX1502，这是一种用于治疗自身免疫适应症的口服小分子。该公司已经开发了 ANX009，一种配制为皮下给药的 C1q 阻断 Fab。
公司简介
公司代码ANNX
公司名称Annexon Inc
上市日期Jul 24, 2020
CEOMr. Douglas E. Love, Esq.
员工数量100
证券类型Ordinary Share
年结日Jul 24
公司地址1400 Sierra Point Parkway
城市BRISBANE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94005
电话16508225500
网址https://annexonbio.com/
公司代码ANNX
上市日期Jul 24, 2020
CEOMr. Douglas E. Love, Esq.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Michael Overdorf
Mr. Michael Overdorf
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
81.75K
-1.03%
Ms. Jennifer Lew
Ms. Jennifer Lew
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
81.33K
-1.35%
Dr. Ted Yednock, Ph.D.
Dr. Ted Yednock, Ph.D.
Executive Vice President, Chief Innovation Officer
Executive Vice President, Chief Innovation Officer
24.66K
-4.33%
Dr. Jamie Dananberg, M.D.
Dr. Jamie Dananberg, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.48K
-90.47%
Dr. Dean Rick Artis, Ph.D.
Dr. Dean Rick Artis, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Ms. Jung E. Choi
Ms. Jung E. Choi
Independent Director
Independent Director
--
--
Dr. William H. Carson, M.D.
Dr. William H. Carson, M.D.
Independent Director
Independent Director
--
--
Mr. Muneer A. Satter, J.D.
Mr. Muneer A. Satter, J.D.
Independent Director
Independent Director
--
--
Mr. William (Bj) Jones, Jr.
Mr. William (Bj) Jones, Jr.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Michael Overdorf
Mr. Michael Overdorf
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
81.75K
-1.03%
Ms. Jennifer Lew
Ms. Jennifer Lew
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
81.33K
-1.35%
Dr. Ted Yednock, Ph.D.
Dr. Ted Yednock, Ph.D.
Executive Vice President, Chief Innovation Officer
Executive Vice President, Chief Innovation Officer
24.66K
-4.33%
Dr. Jamie Dananberg, M.D.
Dr. Jamie Dananberg, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.48K
-90.47%
Dr. Dean Rick Artis, Ph.D.
Dr. Dean Rick Artis, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
12.09%
BlackRock Institutional Trust Company, N.A.
6.94%
Alerce Investment Management, L.P.
6.75%
BVF Partners L.P.
6.38%
Logos Global Management LP
6.02%
Other
61.82%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
12.09%
BlackRock Institutional Trust Company, N.A.
6.94%
Alerce Investment Management, L.P.
6.75%
BVF Partners L.P.
6.38%
Logos Global Management LP
6.02%
Other
61.82%
股东类型
持股股东
占比
Investment Advisor
46.58%
Investment Advisor/Hedge Fund
22.00%
Hedge Fund
18.07%
Private Equity
6.75%
Venture Capital
6.07%
Research Firm
2.33%
Bank and Trust
0.73%
Individual Investor
0.57%
Endowment Fund
0.44%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
324
113.85M
103.77%
-22.18M
2025Q1
339
111.61M
101.75%
-29.54M
2024Q4
329
116.73M
106.58%
-17.05M
2024Q3
303
113.54M
107.51%
-18.37M
2024Q2
291
110.25M
106.60%
-6.79M
2024Q1
286
95.95M
106.04%
-7.64M
2023Q4
274
81.06M
103.56%
+7.91M
2023Q3
277
55.43M
104.79%
-23.79M
2023Q2
273
56.90M
107.89%
-13.92M
2023Q1
276
56.74M
113.00%
-7.66M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
13.26M
12.09%
-961.15K
-6.76%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.62M
6.94%
+55.22K
+0.73%
Mar 31, 2025
Alerce Investment Management, L.P.
7.41M
6.75%
--
--
Mar 31, 2025
BVF Partners L.P.
7.00M
6.38%
--
--
Mar 31, 2025
Logos Global Management LP
6.60M
6.02%
+2.60M
+65.00%
Apr 21, 2025
Redmile Group, LLC
6.30M
5.74%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
5.36M
4.89%
-167.26K
-3.02%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
5.25M
4.78%
--
--
Mar 31, 2025
Bellevue Asset Management AG
5.16M
4.7%
--
--
Mar 31, 2025
Sio Capital Management, LLC
3.40M
3.1%
+1.03M
+43.55%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
iShares Neuroscience and Healthcare ETF
0.56%
ALPS Medical Breakthroughs ETF
0.18%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares Hedge Replication ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.8%
iShares Neuroscience and Healthcare ETF
占比0.56%
ALPS Medical Breakthroughs ETF
占比0.18%
iShares Micro-Cap ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.03%
Avantis US Small Cap Equity ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
ProShares Hedge Replication ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
